<div class="container">

<table style="width: 100%;"><tr>
<td>Zhang</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Meta-analysis of the prognostic role of hormone receptors in endometrial cancer
</h2>

<h3>Description</h3>

<p>This dataset comprises the results from 16 studies assessing the prognostic role of human epidermal growth factor receptor 2 (HER2) in endometrial cancer. These studies were previously identified in a systematic review by Zhang et al. to evaluate the overall risk of several hormone receptors for endometrial cancer survival. 
</p>


<h3>Usage</h3>

<pre><code class="language-R">data("Zhang")</code></pre>


<h3>Format</h3>

<p>A data frame with 20 observations on the following 10 variables.
</p>

<dl>
<dt><code>Study</code></dt>
<dd>
<p>a factor with 16 levels to indicate the study</p>
</dd>
<dt><code>PrimaryAuthor</code></dt>
<dd>
<p>a factor indicating the first author's last name</p>
</dd>
<dt><code>year</code></dt>
<dd>
<p>a numeric vector indicating the publication year</p>
</dd>
<dt><code>Country</code></dt>
<dd>
<p>a factor indicating the source country of the study data</p>
</dd>
<dt><code>Disease</code></dt>
<dd>
<p>a factor indicating the studied disease. Possible levels are <code>EC</code> (endometrial cancer), <code>EEC</code> (endometrioid endometrial cancer) and <code>UPSC</code> (uterine papillary serous carcinoma)</p>
</dd>
<dt><code>N</code></dt>
<dd>
<p>a numeric vector describing the total sample size of each study</p>
</dd>
<dt><code>HR</code></dt>
<dd>
<p>a numeric vector describing the estimated hazard ratio of each study</p>
</dd>
<dt><code>HR.025</code></dt>
<dd>
<p>a numeric vector describing the lower boundary of the 95% confidence interval of <code>HR</code></p>
</dd>
<dt><code>HR.975</code></dt>
<dd>
<p>a numeric vector describing the upper boundary of the 95% confidence interval of <code>HR</code></p>
</dd>
<dt><code>outcome</code></dt>
<dd>
<p>a factor indicating the studied outcome. Possible levels are <code>OS</code> (overall survival) and <code>PFS</code> (progression-free survival)</p>
</dd>
</dl>
<h3>Details</h3>

<p>Eligible studies were identified by searching the PubMed and EMBASE databases for publications from 1979 to May 2014. Data were collected from studies comparing overall survival or progression-free survival in patients with elevated levels of human epidermal growth factor receptor 2 with those in patients with lower levels. 
</p>


<h3>Source</h3>

<p>Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis. World J Surg Oncol. 2015 Jun 25;13:208. 
</p>


<h3>References</h3>

<p>Riley RD, Jackson D, Salanti G, Burke DL, Price M, Kirkham J, et al. Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ. 2017 13;358:j3932. 
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(Zhang)

# Display the hazard ratios for overall survival in a forest plot
ds &lt;- subset(Zhang, outcome=="OS")
with(ds, forest(theta = HR, theta.ci.lb = HR.025, theta.ci.ub = HR.975, 
                theta.slab = Study, xlab = "Hazard ratio of HER2 versus OS", refline = 1))
</code></pre>


</div>